ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,099.96
1.02%
US Tech 100
17,244.80
1.57%
Dow Jones
38,239.66
0.40%
Brent Oil
87.82
-0.39%
Bitcoin
63,115.76
-0.44%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Edgewise Therapeutics Inc (EWTX)

  7. Edgewise Therapeutics Inc (EWTX) News

Edgewise Therapeutics Inc

Edgewise Therapeutics Inc (EWTX)

NASDAQ
16.17
0.23
(1.44%)
Closed April 28 4:00PM
Delayed by 15 minutes
16.17
0.00
(0.00%)
After Hours: 7:57PM
Delayed by 15 minutes

Get an advanced news scanner tailored to your needs by ADVFN

Enhance your trading experience

EWTX News

Official News Only

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Edgar (US Regulatory)
February 22 2024
EWTX (1.44%)

Form 8-K - Current report
Edgar (US Regulatory)
February 22 2024
EWTX (1.44%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 09 2024
EWTX (1.44%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
February 07 2024
EWTX (1.44%)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Edgar (US Regulatory)
January 19 2024
EWTX (1.44%)

EWTX Discussion

View Posts
Whalatane Whalatane 2 weeks ago
Wedbush Reiterates Outperform on Edgewise Therapeutics, Maintains $26 Price Target

I'm surprised stock didn't do better on recent P 2 data ...which was supposed to " de risk " their program

Kiwi
👍️0
Whalatane Whalatane 2 months ago
BOULDER, Colo., February 13, 2024--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EDG-5506 for the treatment of Duchenne.
EDG-5506 is an investigational orally administered small molecule designed to prevent contraction-induced muscle damage in dystrophinopathies, including Duchenne and Becker muscular dystrophy (Becker).
The FDA previously granted EDG-5506 Orphan Drug Designation (ODD) for the treatment of Duchenne and Becker, Rare Pediatric Disease Designation (RPDD) for the treatment of Duchenne, and Fast Track designation for the treatment of Becker.
---------------
Kiwi
👍️0
Whalatane Whalatane 3 months ago
RMB. for what its worth ...both stocks I mentioned are now "technically " over bought ...so some pull back near term is likely
jmo
Kiwi
👍️0
Whalatane Whalatane 3 months ago
RMB. EWTX up 21 % in past week. ( since your post )
VERA ,,,which I think U saw me posting on at the AUPH board ...up 28%
Both I think at 52 wk highs

Usually I find it best to initiate small positions ...follow ..and then if the data still looks good , add on a pullback due to some unrelated event .
Both of these Co's have a lot of data coming out in 2024

Kiwi
👍️0
Monksdream Monksdream 3 months ago
EWTX new 52 week high
👍️0
Monksdream Monksdream 3 months ago
EWTX new 52 week high
👍️0
Whalatane Whalatane 3 months ago
Jonathan C. Fox, M.D., Ph.D., FACC
DIRECTOR
Jonathan C. Fox, M.D., Ph.D., FACC, serves as a member of our board of directors and is the president and chief medical officer for cardiovascular and renal diseases at BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical stage biotechnology company developing novel, genetically targeted therapies. Prior to that, Dr. Fox served as the chief medical officer of MyoKardia, Inc. Additionally, he worked as a consultant at Nigel-Montgomery, LLC, and held various senior R&D positions successively at SmithKline Beecham, Merck Research Laboratories and AstraZeneca. He was also on the faculty of the University of Pennsylvania School of Medicine. Dr. Fox serves on the board at ML BioSolutions and is a trustee of the Lankenau Institute for Medical Research. He is currently an adjunct Professor of Medicine at the Stanford University Cardiovascular Institute. He received his A.B. in biology, his Ph.D. in experimental pathology and his M.D. from the University of Chicago, and completed his training in Internal Medicine and Cardiology at Duke University. Dr. Fox is ABIM Certified in Cardiovascular Diseases and is a Fellow of the American College of Cardiology.


MyoKardia was bt out by BMS
Kiwi
👍️0
Whalatane Whalatane 3 months ago
RMB. You might look at TNYA also ...similar space. Ceo is one very smart guy and is backed by the Column group ( smart team )
Early days tho .
EWTX is far further along

BOTH are high speculative ...so.....etc
Kiwi
👍️0
rosemountbomber rosemountbomber 3 months ago
Kiwi you have peaked my interest in EWTX

The opportunity seems to be here, but I will try to exhibit something I rarely do, namely; patience.

It has risen a bunch in a short time and I hope to pick some up after a bit of a retracement.
👍️0
Whalatane Whalatane 3 months ago
EWTX. Best Co I've seen in this area since MYOK ...which was eventually bt out .
Kiwi
👍️0
Whalatane Whalatane 3 months ago
Impressive presentation at JPM 2024 . Fast tracked but the earliest they are likely to have an approved drug is early 2026...if all goes well
Kiwi
👍️0
goodfree goodfree 3 years ago
Looks like we may have hit the bottom lol
👍️0
goodfree goodfree 3 years ago
Jumped in at $30 today hope we have a good run here
👍️0
crudeoil24 crudeoil24 3 years ago
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) gained 87.5% to close at $30.00 after pricing its IPO at $16 per share.
👍️0
crudeoil24 crudeoil24 3 years ago
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The Company is principally focused on discovering, developing and commercializing treatments for rare muscle disorders. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The Company's lead candidate, EDG-5506, is an orally administered allosteric, selective, fast myofiber (type II) myosin small molecule inhibitor designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). The Company's research programs include EDG-6289, EDG-002 and EDG-003.
👍️0

Your Recent History

NASDAQ
EWTX
Edgewise Therapeutics
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved